Core Viewpoint - A block trade of 1.4 million shares of Sanyou Medical occurred on November 20, with a transaction value of 21.7 million yuan, indicating a discount of 19.40% compared to the closing price on that day [1] Group 1: Transaction Details - The block trade involved a volume of 1.4 million shares and a transaction amount of 21.7 million yuan [1] - The transaction price was set at 15.50 yuan per share, reflecting a significant discount relative to the market [1] - The buyer was from Industrial Securities Co., Ltd. Zhejiang Branch, while the seller was from Huatai Securities Co., Ltd. Beijing Yonghegong Securities Branch [1] Group 2: Recent Trading Activity - Over the past three months, Sanyou Medical has recorded a total of two block trades, with a cumulative transaction value of 64.37 million yuan [1] Group 3: Company Background - Shanghai Sanyou Medical Equipment Co., Ltd. was established on April 19, 2005, with a registered capital of 3.3346 billion yuan [1]

Core Insights - The 24th Chinese Orthopaedic Association (COA) conference showcased significant advancements in orthopedic technology, emphasizing the integration of robotics, navigation, imaging, and biomaterials under the theme "Digital Intelligence in Orthopedics" [2] - The conference attracted 20,188 registered participants and received 37,222 submissions, indicating a strong interest in orthopedic innovations [2] Group 1: Robotics and Navigation Systems - Surgical robots and navigation systems are expanding across various orthopedic fields, moving beyond joint surgeries to include spine, trauma, and sports medicine, focusing on precision and standardization [4] - Companies like Stryker, Tianzhihang, and others are presenting comprehensive orthopedic platforms that integrate imaging, navigation, and robotic arms, forming a closed-loop system for enhanced surgical outcomes [4] - The Trinity system by Tuo Dao Medical demonstrates a unified platform for rapid switching between surgical procedures, showcasing advancements in AI planning and real-time navigation [19] Group 2: Biomaterials and Bone Repair - The competition in bone repair and biomaterials is intensifying, with companies offering innovative solutions such as absorbable screws and 3D-printed bioceramics, focusing on osteogenic activity and infection resistance [4] - Smartbone and other manufacturers are introducing advanced materials that not only fill defects but also promote bone regeneration and integration [4] Group 3: Domestic Innovations - Domestic companies are accelerating the development of high-end joint prosthetics and key materials, with a focus on integrating materials, prosthetic design, and manufacturing processes [4] - The collaboration between local firms and international companies is shifting from product showcases to establishing standards and ecosystems, enhancing the overall orthopedic landscape [4] Group 4: Key Product Launches - Stryker highlighted its latest products, including the Mako robotic system, which integrates multiple surgical techniques for hip and knee replacements, enhancing precision and efficiency [5][7] - Rosenboht signed a strategic partnership with the Chinese University of Hong Kong to advance intelligent surgical technologies, aiming for more precise and minimally invasive orthopedic procedures [12][14] - The launch of the "Panshi Self-Pressing 3D Partition Bone Trabecular Biological Knee Prosthesis" by Jiashite Medical showcases advancements in mechanical stability and biological fixation [40][42] Group 5: Technological Integration - Companies are increasingly focusing on integrating AI and imaging technologies to enhance surgical precision and safety, as seen in the solutions presented by Meiya Optical and other firms [46][50] - The introduction of AR navigation systems by Linyan Medical represents a significant technological advancement, improving the visibility and accuracy of spinal surgeries [53][55] Group 6: Comprehensive Solutions - The conference highlighted the importance of comprehensive solutions that encompass preoperative planning, intraoperative guidance, and postoperative evaluation, as demonstrated by various exhibitors [4][60] - Companies like Weigao and others are showcasing integrated solutions that leverage digital technologies to enhance the entire orthopedic treatment process [100][102]

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-20 | 三友医疗 | ୧୫୫୦୫ ୧ | 15.5 | 2170 | 140 | | 华泰证券股份有限 公司北京雍和宫证 | 11月20日，三友医疗大宗交易成交140万股，成交额2170万元，占当日总成交额的60.21%，成交价15.5元，较市场收盘价19.23元折价19.4%。 ...

Investment Rating - The investment rating for the company is "Buy" with a previous rating of "Buy" as well [1] Core Views - The company reported a revenue of 391 million RMB for the first three quarters of 2025, representing a year-on-year growth of 17.65%. The net profit attributable to the parent company was 61.98 million RMB, showing a significant increase of 623.19% year-on-year [4] - The company is experiencing rapid growth in its ultrasonic bone knife business and has begun to make breakthroughs in its international operations, leading to a positive outlook for future development [4][6] Summary by Relevant Sections Financial Performance - The company adjusted its profit forecast, expecting net profits for 2025-2027 to be 115 million, 179 million, and 259 million RMB respectively, with corresponding EPS of 0.34, 0.54, and 0.78 RMB. The current stock price corresponds to PE ratios of 55.7, 35.7, and 24.7 times for the respective years [6][8] - The company’s revenue for Q3 was 142 million RMB, a year-on-year increase of 17.44%, with a net profit of 25.38 million RMB, up 268.13% year-on-year [9] Business Segments - The ultrasonic bone knife business showed impressive performance, with revenue of 115 million RMB in the first three quarters, a growth of 52.21% year-on-year. The company has completed its performance commitments for 2025 [9] - The international business is progressing rapidly, with the French subsidiary Implanet achieving revenue of 2.92 million euros in Q3, a growth of 26.37%, and the US market contributing 1.06 million euros, up 22.21% [9] Future Outlook - The company’s innovative products are entering a harvest phase, with recent approvals for new products enhancing its domestic product line. This is expected to stabilize domestic business growth [9]

Core Viewpoint - Q3 performance met expectations, with stable growth in domestic terminal surgeries and sales, and continuous performance growth in international business, especially in the US market [1][4] - The company is expected to achieve steady growth in domestic spinal business and continued expansion in ultrasound bone knife and overseas business in Q4 and next year [1][5] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 391 million yuan (+17.65%) and a net profit attributable to shareholders of 62 million yuan (+623.19%), with a non-recurring net profit of 49 million yuan (+1737.69%) [2][4] - Q3 single-quarter revenue was 142 million yuan (+17.44%) and net profit attributable to shareholders was 25 million yuan (+268.13%) [4] - The company’s gross profit margin improved to 74.31% (+4.63 percentage points) [6] Business Growth - The domestic spinal business is expected to return to steady growth following the clearance of the impact from spinal centralized procurement [5][7] - The ultrasound bone knife business is anticipated to grow rapidly as its penetration rate in the domestic market is currently low [5][7] - The company’s overseas revenue from the French subsidiary Implanet reached 291.59 million euros, with the US market becoming the largest market for Implanet [5] Future Outlook - The company is projected to achieve revenues of 545 million yuan, 675 million yuan, and 840 million yuan from 2025 to 2027, with year-on-year growth rates of 20.2%, 23.8%, and 24.4% respectively [7] - Net profit attributable to shareholders is expected to reach 90 million yuan, 130 million yuan, and 167 million yuan during the same period, with significant growth rates [7]

Investment Rating - The industry investment rating is maintained as "Outperform the Market" [2][57]. Core Insights - The orthopedic consumables sector has shown continuous improvement in performance during the first three quarters of 2025, with a positive trend in overseas expansion [3][10]. - The overall revenue of the orthopedic consumables sector increased by 17% year-on-year for Q1-Q3 2025, with net profit attributable to shareholders rising by 81% [5][10]. - The gross profit margin for the sector improved to 66% in Q1-Q3 2025, reflecting effective cost control and optimization [4][10]. - The trend of companies actively pursuing international markets is expected to become a significant growth driver [10][27]. Summary by Sections 1. Orthopedic Consumables Q3 2025 Report Analysis - The orthopedic consumables sector's revenue for Q1-Q3 2025 reached 49.18 billion, with a year-on-year growth of 17% [9]. - The gross profit margin for Q3 2025 was reported at 67%, an increase of 2.06 percentage points compared to the previous year [10]. - The net profit attributable to shareholders for Q3 2025 doubled year-on-year, indicating significant performance improvement [10]. 2. Segment Analysis - The joint business segment has seen stable growth due to the continuation of centralized procurement and an increase in both volume and price for leading companies [19][24]. - The spinal segment is experiencing a steady execution of centralized procurement, with leading domestic brands increasing their market share [25]. - The trend of domestic companies expanding overseas is gaining momentum, with a focus on product innovation and international development [27][29]. 3. Related Company Q3 Report Summary - Major companies in the sector, such as Dabo Medical, Weigao Orthopedics, and Spring Medical, have shown strong revenue growth and profitability improvements in Q3 2025 [12][41][45]. - Dabo Medical reported a revenue of 18.76 billion, up 22.69% year-on-year, with a net profit of 4.25 billion, reflecting a 77.03% increase [45]. - Spring Medical achieved a remarkable revenue growth of 109.5% in Q3 2025, turning a previous loss into a profit of 770.6 million [33].

Core Points - The company held its fifth extraordinary general meeting of shareholders on November 7, 2025, with no resolutions being rejected [2][4] - All proposed resolutions were approved during the meeting, including a resolution to provide guarantees for a controlling company and to reappoint the accounting firm [4][5] - The meeting was presided over by the chairman, Michael MingYan Liu, and attended by all nine current directors and key executives [3][4] Fundraising Information - The company successfully raised a total of RMB 1,075,950,160.00 from its initial public offering (IPO) in 2020, with a net amount of RMB 978,057,381.28 after deducting issuance costs [10] - In a subsequent issuance, the company raised RMB 213,999,988.12, with a net amount of RMB 203,920,127.60 after related expenses [12] - The company has established special accounts for the management of raised funds, ensuring compliance with relevant regulations [14] Account Cancellation - The company decided to cancel a special fundraising account at Shanghai Pudong Development Bank due to the completion of the use of excess funds from the IPO [15] - The cancellation of the account has been completed, and the corresponding regulatory agreement has been terminated [15]

Fundraising Overview - The company successfully completed its initial public offering (IPO) on March 12, 2020, raising a total of RMB 1,075,950,160.00, with a net amount of RMB 978,057,381.28 after deducting issuance costs [2] - The company was also approved to issue shares for asset acquisition and raise matching funds, totaling RMB 213,999,988.12, with a net amount of RMB 203,920,127.60 after related expenses [3] Fund Management - The company has established a dedicated account for fundraising, adhering to regulatory requirements and ensuring strict supervision of fund usage [5] - The company has signed a tripartite supervision agreement with its financial advisor and the bank holding the funds to ensure proper management [4] Account Cancellation - The company has decided to cancel a specific fundraising account at Shanghai Pudong Development Bank, as the excess funds from the IPO have been fully utilized [7] - The cancellation process has been completed, and the corresponding supervision agreement has been terminated [7]

Group 1 - The company announced the completion of the use of over-raised funds from its initial public offering, which were stored in a dedicated account at Shanghai Pudong Development Bank [1] - The dedicated fundraising account will be canceled to facilitate the management of the company's financial accounts [1] - The company has completed the cancellation procedures for the dedicated fundraising account and terminated the corresponding storage supervision agreement with the sponsor and the bank [1]

证券代码：688085 证券简称：三友医疗 公告编号：2025-086 上海三友医疗器械股份有限公司 关于注销部分募集资金专项账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）首次公开发行股票 经上海证券交易所科创板上市委员会 2020 年 1 月 8 日审核同意，并经中国 证券监督管理委员会于 2020 年 3 月 12 日《关于同意上海三友医疗器械股份有限 公司首次公开发行股票注册的批复》（证监许可〔2020〕402 号）同意注册，公 司获准向社会公开发行人民币普通股 51,333,500 股，每股面值人民币 1.00 元， 每股发行价为人民币 20.96 元，合计募集资金人民币 1,075,950,160.00 元，扣除 各 项 发 行 费 用 （ 不 含 税 ） 人 民 币 97,892,778.72 元 后 ， 募 集 资 金 净 额 为 978,057,381.28 元。上述募集资金已全部到位，并由立信会计师事务所（特殊普 通合伙）验证并出具"信会师报字[2020]第 ZA ...